ArticleScientific reports2026
Longitudinal associations of DNA-methylation of OXT, SLC6A4 and NR3C1 genes with the treatment response in patients with depression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered methylation of genes implicated in depression has been proposed as a biomarker for treatment response. Yet, replication remains inconsistent while methodological concerns have grown. In a matched case control study, we investigated DNA-methylation of the NR3C1 (glucocorticoid receptor), SLC6A4 (serotonin transporter), and OXT (oxytocin) genes in peripheral blood of patients with depression (N = 66) and healthy controls (N = 66) at baseline and after two weeks of inpatient treatment. We tested group differences, convergence over time, associations with changes in depression severity, and relations to mRNA abundance. At baseline, OXT methylation was significantly lower in patients, but this effect disappeared when adjusting for neutrophil and lymphocyte abundance, highlighting the impact of cellular composition on methylation measures. Despite significant decrease in depression severity, methylation changes in none of the candidate genes were associated with treatment response. In healthy controls, two OXT CpG sites showed negative associations with mRNA abundance, which were absent in patients. These findings emphasize the importance of rigorous control of confounders, especially blood cell composition, in psychiatric epigenetics. Our results add to accumulating null findings for stress- and serotonergic-related genes and caution against overinterpreting peripheral methylation signals as biomarkers for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.